1.Name of the securities:LUMOSA THERAPEUTICS CO., LTD.

2.Trading date:2024/08/08~2024/08/14

3.Amount, unit price, and total monetary amount of the transaction:
Transaction amount: 350,000 common shares ;
Unit price (NTD$): an average of 227.59 per share ;
Total monetary amount of transaction: NTD$79,656,000

4.Gain (or loss) through disposal (not applicable in case of acquisition of securities): Disposal gain of NTD$74,406,000

5.Relationship with the underlying company of the trade:None

6.Current cumulative amount held, monetary value, and shareholding percentage of cumulative holdings of the securities being traded (including the current trade), and status of any restriction of rights (e.g., pledges):
Cumulative amount held:”
Remainder cumulative amount held:810,000 common shares;
Remainder cumulative monetary amount held: NTD$195,615,000;
Remainder shareholding percentage: 0.49%;
Restriction of rights: None.

7.Current ratio of securities investment (including the current trade) to the total assets and equity attributable to owners of parent as shown in the most recent financial statement and working capital as shown in the most recent financial statement as of the present, as listed in the Regulations Governing the Acquisition and Disposal of Assets by Public Companies: Ratio to total assets:
Ratio to total assets: 16.61% ；
Ratio to owners’equity: 17.66%；
Working capital: NTD$700,184 thousand.

8.Concrete purpose of the acquisition or disposal: Investment profit realization

9.Whether the directors expressed any objection to the current transaction: None

10.Whether the counterparty of the current transaction is a related party: No

11.Trading counterparty and its relationship to the Company: NA

12.Date of the board of directors’ resolution: NA

13.Date of ratification by supervisors or approval by the audit committee: NA

14.Any other matters that need to be specified: None